Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Cutaneous Lymphomas
Would you consider using a JAK inhibitor for CTCL?
Related Questions
In an older patient with pembrolizumab-associated chronic eczematous dermatitis—worsened by dupilumab and with biopsies showing spongiotic dermatitis with atypical lymphocytes, would a trial of a JAK inhibitor be appropriate while monitoring for possible early CTCL?
Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?
How soon after stopping oral steroids can patch testing be performed?
What cosmetic options can you provide to patients with facial discoid lupus that seems stable?
How do you counsel patients who inquire about microplastics in their cosmetics or physician-dispensed products given emerging associations with conditions such as psoriasis, eczema, lupus, and hormonal disruption?
How do you counsel patients with pemhigus on the main safety benefits of a low or ultra low dose rituximab regimen?
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
